C4 Therapeutics, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will supply elranatamab (ELREXFIO®?), a B-cell maturation antigen CD3 targeted bispecific antibody (BCMAxCD3 bispecific), to C4T for its upcoming Phase 1b trial. The Phase 1b trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab as a second line or later therapy for patients with multiple myeloma. This Phase 1b trial, which is expected to initiate in Second Quarter 2026, will seek to establish an optimal dose for cemsidomide in combination with elranatAMab.
Under the terms of the Agreement, Pfizer will supply el Granatamab at no cost while C4T will sponsor and conduct the trial. Data generated from the cemsidomide Phase 1 trial in relapsed/refractory multiple myeloma demonstrate robust T-cell activation and cytokine expression across multiple doses. By activating immune T-cells, cemsidomide, when combined with a BCMAxCD3 bispespecific such as elranatamab, may amplify the anti-myeloma immune response and lead to higher quality of responses.
